Skip to content

Insider · CIK 0001942407

Scott T. Rottinghaus

officer

Files at ENTA (ENANTA PHARMACEUTICALS INC). First filing Dec 10, 2024, latest Dec 10, 2024.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $6,980 sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

ENTA: ENANTA PHARMACEUTICALS INC

ENTAOct 9, 2026 · close 12.50

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
10Weak
ENTAsell 610b5-1
ENANTA PHARMACEUTICALS INC
$6,980
866 shares
-5%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Aug 8, 2025ENTA
ENANTA PHARMACEUTICALS INC
FTax withholding
Common Stock
-2,217$6.99$15k22,590Aug 8, 2025
Feb 12, 2025ENTA
ENANTA PHARMACEUTICALS INC
AGrant or award
Common Stock
+9,750$0.00$027,668Feb 14, 2025
Feb 12, 2025ENTA
ENANTA PHARMACEUTICALS INC
FTax withholding
Common Stock
-2,861$5.59$16k24,807Feb 14, 2025
Dec 6, 2024ENTA
ENANTA PHARMACEUTICALS INC
SOpen-market sale
Common Stock10b5-1
-866$8.06$6,98017,918Dec 10, 2024
Nov 27, 2024ENTA
ENANTA PHARMACEUTICALS INC
AGrant or award
Stock Option (right to buy)derivative
+87,000$0.00$087,000Nov 27, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Scott T. Rottinghaus: insider trades and track record | InsiderTell